Authors: B. Macešková 1; R. Blechová 2; H. Ondrašíková 1 Authors‘ workplace: Ústav aplikované farmacie, Farmaceutická fakulta VFU, Brno přednosta doc. RNDr. J. Kolář, CSc. 1; Ústav humánní farmakologie a toxikologie Farmaceutická fakulta VFU, Brno přednosta doc. MUDr. J. Nečas, CSc. 2 Published in: Prakt. Lék. 2005; 85(3): 170-173 Category: General Medicine
Hypnotics may pose a risk for the patient, namely when they are not prescribed rationally. Prescriptions of hypnotics have been followed up at five pharmacies over a period of 12 months. In the course of ten months before the amendment of Act No. 167/1998 Dig., the ratio of prescriptions of benzodiazepine and non-benzodiazepine hypnotics was 57 : 43 expressed in RDD; the most frequently prescribed drug was Rohypnol tbl (1 mg of active substance, flunitrazepam), the most frequently prescribed active substance was flunitrazepam (in a single product). In the course of the first two months following the Amendment, the ratio of prescribed benzodiazepine and non-benzodiazepine hypnotics changed to 45 : 55, expressed in RDD. In first place was then the prescription drug Hypnogen tbl 15, the mostfrequently prescribed active substance being zolpidem (in 7 different products). Hypnotics were prescribed overwhelmingly to patients of the 61–80 year age group, more to females than to males, more frequently in the autumn and winter months. In a continued follow-up at one of the former pharmacies over another seven months there has been found a shift in the ratio of prescribed benzodiazepine and non-benzodiazepine hypnotics down to 24 : 76. The prescribing of the product Rohypnol tbl has a declining trend.
Key words: hypnotics – benzodiazepines – non-benzodiazepines – prescriptions.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
